Acylglycerol acyltransferase-like protein MGAT-X1 and uses thereof
AssigneeBayer Schering Pharma Aktiengesellschaft
InventorsStefan Golz, Ulf Brüggemeier, Bernhard Weingärtner, Andreas Geerts
Life of this patent
Estimating the term…
Loading patent…
AssigneeBayer Schering Pharma Aktiengesellschaft
InventorsStefan Golz, Ulf Brüggemeier, Bernhard Weingärtner, Andreas Geerts
Estimating the term…
The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
An isolated nucleic acid molecule selected from a group consisting of:
A pharmaceutical composition comprising a nucleic acid molecule selected from the group consisting of:
A pharmaceutical composition comprising a vector comprising a nucleic acid molecule selected from a group consisting of:
Dependencies are inferred from the claim text.